LPL Financial LLC Buys 34,487 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

LPL Financial LLC raised its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 10.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 364,191 shares of the medical equipment provider’s stock after acquiring an additional 34,487 shares during the period. LPL Financial LLC owned about 0.10% of Intuitive Surgical worth $190,883,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Atala Financial Inc bought a new position in Intuitive Surgical during the 4th quarter valued at $25,000. Berbice Capital Management LLC bought a new stake in shares of Intuitive Surgical during the 4th quarter worth $26,000. BankPlus Trust Department bought a new stake in shares of Intuitive Surgical during the 4th quarter worth $28,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Intuitive Surgical during the 4th quarter worth $31,000. Finally, Decker Retirement Planning Inc. bought a new stake in shares of Intuitive Surgical during the 4th quarter worth $36,000. 83.64% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Intuitive Surgical

In other news, EVP Brian Edward Miller sold 8,900 shares of Intuitive Surgical stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $485.07, for a total transaction of $4,317,123.00. Following the completion of the sale, the executive vice president now directly owns 5,758 shares of the company’s stock, valued at approximately $2,793,033.06. The trade was a 60.72 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Amal M. Johnson sold 4,635 shares of Intuitive Surgical stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the sale, the director now directly owns 12,275 shares of the company’s stock, valued at $6,955,015. This represents a 27.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 33,754 shares of company stock valued at $17,691,621 in the last three months. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG opened at $492.49 on Monday. The firm has a fifty day moving average price of $562.24 and a two-hundred day moving average price of $532.03. Intuitive Surgical, Inc. has a one year low of $364.17 and a one year high of $616.00. The company has a market cap of $175.41 billion, a price-to-earnings ratio of 76.83, a PEG ratio of 5.85 and a beta of 1.43.

Analysts Set New Price Targets

ISRG has been the topic of a number of recent analyst reports. Royal Bank of Canada lifted their target price on Intuitive Surgical from $611.00 to $641.00 in a research note on Monday, January 27th. UBS Group lifted their target price on Intuitive Surgical from $500.00 to $560.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Leerink Partners lifted their target price on Intuitive Surgical from $490.00 to $548.00 in a research note on Monday, January 27th. Barclays lifted their target price on Intuitive Surgical from $610.00 to $674.00 in a research note on Monday, January 27th. Finally, CICC Research initiated coverage on Intuitive Surgical in a report on Monday, January 27th. They issued a “neutral” rating and a $550.00 price objective for the company. One research analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus target price of $611.86.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.